Retatrutide 20 mg is a higher-concentration format of the triple-agonist peptide Retatrutide. Each vial contains 20 mg of lyophilized peptide for research applications requiring larger working stock.
Research Profile
- Triple-agonist activity across GIP, GLP-1, and glucagon receptors
- Studied in metabolic, energy-balance, and glucose-handling research models
- Larger vial format for high-throughput studies
- QC verified by HPLC and mass spectrometry
Specifications
- Compound: Retatrutide (LY3437943)
- Dosage: 20 mg per vial
- Purity: ≥ 98% (HPLC)
- Form: Lyophilized powder
- Storage: 2–8 °C (lyophilized); –20 °C (reconstituted)
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
